London Pharma and Chemicals Group acquires nutraceutical vegan products

London Pharma and Chemicals Group has acquired two vegan products for use in food supplements, Vollagen and Phytodroitin.

Vollagen is considered a vegan alternative to collagen, as it is made up of the same amino acids found in human collagen, but derived from plant sources. It is produced using a proprietary fermentation and microencapsulation process with a starting material of non-GMO corn starch.

Consumers who used a daily dose of Vollagen are said to have identified many skincare benefits within 30 days of repeated use, such as improvements in hydration and radiance, and a reduction in the appearance of wrinkles, fine-lines, blemishes and breakouts. The study results were achieved with the consumption of 1g of Vollagen per day, in comparison to the majority of traditionally-derived collagen supplements that typically use a daily dose of 5-10g per day.

Made from a blend of seaweed extracts, Phytodroitin is a plant-based alternative to chondroitin, which typically derives from shark or avian cartilage. Chondroitin is a dietary supplement that has been widely used for many years to support bone and joint care. The plant-based alternative, Phytodroitin, mimics the structure of chondroitin to make it suitable for vegans and vegetarians.

Daniel Straus, London Pharma and Chemicals Group chairman, said: “We see huge potential for Vollagen and Phytodroitin to transform the food supplement industry. As consumers seek out ever healthier alternatives that do not have a negative impact on the environment, we see this as the start of a new wave of vegan alternatives to existing nutraceutical products that are significantly more sustainable and broaden the market to include those who do not consume animal-derived products.”

Vollagen and Phytodroitin are distributed by ProTec Nutra, provider of plant based ingredients for the global nutraceutical and F&B markets.

Financial details of the acquisitions were not disclosed.